Upwards of 700,000—perhaps as many as 1.6 million—US COVID-19 survivors haven't recovered their sense of smell after more than 6 months, according to a research letter yesterday in JAMA Otolaryngology-Head & Neck Surgery.
New research from the Mayo Clinic shows monoclonal antibodies reduce the risk of hospitalization 77% in 1,395 patients who had breakthrough COVID-19 infections. The research was published yesterday in the Journal of Infectious Diseases.
A survey of 164 New York physicians found that one in five were severely distressed during their first COVID-19 triage decisions and last-minute training did not appear to alleviate stress, according to a study yesterday in Disaster Medicine and Public Health Preparedness.
Direct COVID-19 deaths may be more than double previous estimates, according to a report yesterday by the University of Washington's Institute for Health Metrics and Evaluation (IHME).
A study published today in the Centers for Disease Control and Prevention's (CDC's) Morbidity and Mortality Weekly Report (MMWR) highlights factors that may increase the risk of infection with SARS-CoV-2, the virus that causes COVID-19, among US poultry facility workers—especially those who are foreign-born.
The Global Antibiotic Research and Development Partnership (GARDP) this week announced a partnership with Venatorx Pharmaceuticals to accelerate development of an investigational beta-lactam/beta-lactamase inhibitor combination for treating multidrug-resistant hospital infections.
Public Health England (PHE) today confirmed that a person in the southwest of England has been diagnosed as having monkeypox, likely contracted after a recent visit to Nigeria.
The United Kingdom documented its first cases of the rare virus last year, in two patients who also likely contracted the disease in Nigeria, plus a case involving a healthcare worker—the first instance of spread of the disease in the country.
Pakistan, Nigeria, the Democratic Republic of the Congo (DRC), and Angola each reported new cases of vaccine-derived polio, according to the latest weekly update today from the Global Polio Eradication Initiative (GPEI), and Pakistan also confirmed cases involving the wild-type virus.
The vaccine produced a strong immune response and fewer lesions than ACAM2000.
The Global Polio Eradication Initiative (GPEI) in its latest weekly update today noted new cases of polio in Pakistan, Angola, and Myanmar—all countries battling ongoing outbreaks of wild or vaccine-derived poliovirus.
